Menu
Search
|

Menu

Close
X

Abeona Therapeutics Inc ABEO.OQ (NASDAQ Stock Exchange Capital Market)

12.50 USD
+0.45 (+3.73%)
As of Feb 17
chart
Previous Close 12.05
Open 11.85
Volume 398,849
3m Avg Volume 270,722
Today’s High 13.15
Today’s Low 11.65
52 Week High 22.70
52 Week Low 4.55
Shares Outstanding (mil) 40.29
Market Capitalization (mil) 713.08
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
1
FY15
1
EPS (USD)
FY17
-0.468
FY16
-0.637
FY15
-0.523
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
845.89
5.77
Price to Book (MRQ)
vs sector
8.00
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-29.33
14.43
Return on Equity (TTM)
vs sector
-30.75
16.13

EXECUTIVE LEADERSHIP

Steven Rouhandeh
Executive Chairman of the Board, Since 2015
Salary: $370,000.00
Bonus: $220,000.00
Timothy Miller
President, Chief Executive Officer, Director, Since 2015
Salary: $359,000.00
Bonus: $148,000.00
Jeffrey Davis
Chief Operating Officer, Since 2017
Salary: $334,000.00
Bonus: $266,000.00
David Nowotnik
Senior Vice President - Research and Development, Since 2016
Salary: $129,000.00
Bonus: --
Harrison Wehner
Senior Vice President - Plasma, Since 2017
Salary: $97,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3333 Lee Pkwy Ste 600
DALLAS   TX   75219-5117

Phone: +1214.9055100

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

SPONSORED STORIES